Although it is already known that GLP-1RAs and SGLT2-is are the first line of treatment in T2DM when there is overt cardiovascular disease or CKD, or when there is a high risk of CVD, such results extend the possible eligibility criteria for initiating these agents. The gene discussed is SLC5A2; the disease is chronic kidney disease.